Dyadic International Inc (NASDAQ:DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn’t simply a reproduction or tie-in to the big pharma game right now.
DYAI has a new approach that isn’t new-age quote-unquote “science”, but a powerful new potential solution that holds the capacity to possibly become better able to deal with new variants and even possibly better able to drive cheap and efficient production capable of vaccinating the world compared to others such as: Astrazeneca (NASDAQ:AZN), Moderna Inc. (NASDAQ:MRNA), Novavax Inc. (NASDAQ:NVAX), Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), and Biontech (NASDAQ:BNTX).
The company has now started to move toward collaborations that could produce the next major breakthrough in fighting Covid-19 over the long term, including vaccines that cover Covid-19 variants. In fact, DYAI believes it can produce trivalent and quadrivalent Covid-19 vaccines – ie a single vaccine that can cover three or even four variants of the virus simultaneously.
According to materials published by Dyadic International Inc (NASDAQ:DYAI), the C1 microorganism that forms the basis of its technology enables the development and large-scale manufacture of low-cost proteins and has the potential to be further developed into a safe and efficient expression system that may help speed up the development of biologic vaccines and drugs at commercial scales, while lowering production costs and improving performance at the same time.
There is still a lot of testing to be done. But the building blocks are potentially in place, and the company is moving forward with data-gathering activities that may produce game-changing results.
Dyadic’s Technology and Production Vectors
The technological breakthrough in play from DYAI has, most centrally, to do with vaccine production and the biological technology required to produce vaccines in large quantities.
Proteins associated with vaccine production are produced through a “vector”. The baculovirus–insect cell expression system is a commonly used vector and has been extensively utilized for the production of many recombinant proteins and commercial vaccines.
For example, for the production host of antigens for the Schmallenberg virus (SBV), we have comparative data. SBV antigens have been produced through both baculovirus–insect cell expression systems and through DYAI’s fungal system. As it turns out, the SBV antigen from C1 produced 300 times greater yields than the SBV antigen from baculovirus and was more stable.
Additionally, the C1 SBV antigen was shown to be safe and very effective (Full Protection) in protecting cattle and mice from the SBV.
DYAI believes its system could represent a breakthrough on a potentially significant scale as a biopharmaceutical gene expression platform. The key differentiating factor is that the DYAI system is based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism is technically a fungal body, which differentiates its platform from other major vaccine programs.
Based on its SBV results, additional fully funded animal trials are continuing in 2021 with C1 expressed antigens for SBV and RVFV and to generate additional safety and efficacy data. The company is also beginning to test its platform as a system for generating results in the battle against Covid-19.
Why it Matters
According to Bloomberg, enough doses have now been administered to fully vaccinate 8.6% of the global population—but the distribution has been lopsided. Countries and regions with the highest incomes are getting vaccinated about 25 times faster than those with the lowest.
But new and potentially deadly variants can emerge anywhere and still end up taking over the world.
New variants are popping up almost weekly, it seems. Eventually, one will emerge that falls outside the efficacy range of our currently approved vaccines. The more people on the planet that remain unvaccinated, the faster such a threat will become a manifest reality.
In other words, either we find a faster, cheaper means of reaching vaccine-induced herd immunity, or we may be headed back into a new chapter in an ongoing pandemic crisis.
If DYAI’s CI-based platform is able to prove itself as a solution that can produce more vaccine doses at a lower cost without sacrificing efficacy, then it could represent an important breakthrough that changes the course toward a less vulnerable path.
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.